Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 65 Days Sales Outstanding is 186.82 as of Dec. 2025, which is 34% below its 10-year median of 282.61. GuruFocus rates CASBF with a GF Score™ of 65/100 and a GF Value™ of $9.11 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 946 Drug Manufacturers companies, CanSino Biologics ranks worse than 98.1% on this metric.
CanSino Biologics (OTCPK:CASBF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CanSino Biologics Days Sales Outstanding Related Terms
CanSino Biologics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Days Sales Outstanding falls into.
CanSino Biologics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 186.82 mean?
CanSino Biologics (CASBF) has a Days Sales Outstanding of 186.82 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CanSino Biologics and its competitors. This is 34% below median its historical median of 282.61. Over the past decade, CanSino Biologics' Days Sales Outstanding has ranged from 7.59 to 798.51. According to the industry distribution chart, CanSino Biologics ranks #928 out of 946 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is CanSino Biologics' Days Sales Outstanding too high?
CanSino Biologics' current Days Sales Outstanding of 186.82 is 34% below median its 10-year median of 282.61. Over the past 10 years, this metric has ranged from a low of 7.59 to a high of 798.51. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. CanSino Biologics' value of 186.82 is 159.9% above this industry median. Based on the distribution chart, CanSino Biologics ranks #928 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #928 out of 946 companies for Days Sales Outstanding. This places CanSino Biologics in the lower half of its industry. The industry median Days Sales Outstanding is 71.89. CanSino Biologics' value of 186.82 is 159.9% above this benchmark. Historically, CanSino Biologics' own Days Sales Outstanding has ranged from 7.59 to 798.51 over the past decade. While the company's 10-year median is 282.61 vs. the industry median of 71.89, CanSino Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Days Sales Outstanding of 186.82 is 159.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Days Sales Outstanding is 186.82, which is 34% below median its own 10-year median of 282.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.11, compared to a current price of $4.60 — trading 49.5% below its estimated fair value. The current Days Sales Outstanding is 186.82, which is 34% below median its 10-year median of 282.61 and 159.9% above the Drug Manufacturers industry median of 71.89. CanSino Biologics' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Days Sales Outstanding is 186.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $4.60 is trading 49.5% below its estimated GF Value™ of $9.11.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Days Sales Outstanding: 186.82 (34% below median its 10-year median of 282.61)
GF Value™: $9.11 vs. price of $4.60 (49.5% below fair value)
Industry Position: 159.9% above the Drug Manufacturers median (#928 of 946)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score
Get the complete analysis for CASBF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
